Dextenza controls post-operative inflammation after MIGS

Patients receiving MIGS with dexamethasone ophthalmic insert 0.4 mg (Dextenza; Ocular Therapeutix) after concurrent cataract surgery had the same inflammation control as those who received MIGS with topical prednisolone, according to a poster presented at the Women in Ophthalmology Meeting 2021 Summer Symposium.

In this retrospective observational study, post-operative inflammation at months 1 and 3 was recorded in 84 eyes undergoing MIGS with Dextenza (n = 42) or topical prednisolone (n = 42). All patients received intra-cameral antibiotics and had MIGS performed after concurrent cataract surgery.

At months 1 and 3, there was no difference in post-operative inflammation between the 2 groups, and a decrease in the number of IOP lowering drops and IOP was observed in each group. The rate of IOP spike was 4.8% and 5.4% in the topical prednisolone group and Dextenza group, respectively.

Reference
Jackson K, et al. Comparing post-op inflammation in MIGS after Dextenza or Topical Prednisolone. Presented at: Presented at: WIO 2021 Summer Symposium.